Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual Meeting Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first...

Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update Dr. Zeldis adds extensive clinical development expertise to Board BND-22, a novel immuno-oncology agent that targets the ILT2 receptor, on track for Q4 2020 IND submission MISGAV, Israel, June 01,...

Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory Board MISGAV, Israel, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held Israeli biotech company, developing novel immunotherapies for cancer and a...